Cancer prevention by bovine lactoferrin: from animal studies to human trial
- 469 Downloads
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers and, despite improved colonoscopic screening, CRC is a leading cause of death from cancer. Administration of bovine lactoferrin (bLF) suppresses carcinogenesis in the colon and other organs of test animals, and recently it was shown that ingestion of bLF inhibits the growth of adenomatous polyps in human patients. Here we review work which established bLF as an anti-carcinogenic agent in laboratory animals and the results of a clinical trial which demonstrated that bLF can reduce the risk of colon carcinogenesis in humans.
KeywordsBovine lactoferrin Chemoprevention Colorectal cancer
- de la Rosa G, Yang D, Tewary P et al (2008) Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J Immunol 180:6868–6876Google Scholar
- Iigo M, Shimamura M, Hirano S et al (2005) Cancer prevention and anti-metastatic effects by oral administration of bovine lactoferrin. In: Takuji T, Hiroyuki T (eds) Carcinogenesis and modification of carcinogenesis. Research Signpost, Kerala, India, pp 229–242Google Scholar
- Kozu T, Iinuma G, Ohashi Y et al (2009) Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res (Phila Pa) 2:975–983Google Scholar
- Levin B, Lieberman DA, McFarland B et al (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58:130–160CrossRefPubMedGoogle Scholar